NFKB1 and glioblastoma: Waters et al. identified two cytokines, IL-1β and oncostatin M (OSM), that activate Re1B/p50 complexes through the NF-κB pathway, causing an increase in pro-inflammatory cytokines in GBM cells and a worse prognosis in patients [69].